Writing for The Atlantic, Dr. Ezekiel Emanuel accuses the biopharmaceutical industry of being “deceptive” when it seeks to explain the cost of prescription drugs. But in making this claim, Dr. Emanuel is guilty of engaging in some of his own acts of deception. For starters, drug prices are not …

Last night, U.S. Senator Pat Roberts (R-Kan.) accepted BIO’s Lifetime Achievement Award, which recognized his leadership, service and commitment to advancing sound public policy that benefits America’s agricultural innovation and life-saving medical treatments. As a leader on both the Senate…

Risky. Costly. Time consuming. Rewarding. Those few words help describe a biopharmaceutical ecosystem where 90% of all clinical development programs fail, but where lives are transformed each time a potential drug candidate crosses the R&D finish line. But as Dr. Ted Love, president and CEO of…

Writing for Morning Consult, Dr. Lucy Langer, a clinical oncologist with Compass Oncology in Portland, Oregon, applauds the administration’s goal of lowering drug prices, but warns of the dangers associated with proposals like the International Pricing Index (IPI) that will – in the words of Dr…

A piece by Peter J. Pitts, a former FDA Associate Commissioner and President of the Center for Medicine in the Public Interest, describes the role of pharmacy benefit managers (PBMs) and tactics they use to shift a growing portion of prescription drug costs to patients and consumers. “In the…

While many were watching the drug pricing debate unfold on Capitol Hill, the Kentucky Cabinet for Health and Family Services published a report exposing drug cost middlemen, better known as pharmacy benefit managers (PBMs), for their role in marking up prices for common drugs and pocketing the…

For years, BIO has been urging both state and federal policymakers to adopt responsible solutions that would make prescription drugs more affordable for America’s patients. At times, our advocacy work includes the need to raise concerns with some of the policy proposals being discussed. That’s the…

Despite considerable pressure directed squarely at biotech innovators from politicians of every stripe, biotech executives remained focused on finding the medicines of tomorrow at the BIO CEO & Investor Conference. New York, host of the event for the past 21 years, continues to be a premier…

In his State of the Union address, President Trump called on Congress to “do more” to lower drug costs in the United States. Already, the U.S. Department of Health and Human Services (HHS) has proposed piloting an International Pricing Index payment model, tying costs for drugs under Medicare Part…

BIO is out with a new report illustrating the negative impact of Sarbanes-Oxley 404(b) on biopharmaceutical emerging growth companies (Bio-EGCs), demonstrating how this regulatory requirement harms innovation and capital formation without any corresponding investor benefit. In the report, Science…